TGTX TG Therapeutics Inc

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Bank of America Securities 2023 Health Care Conference, being held at the Encore Hotel, in Las Vegas, NV on Tuesday May 9th through Thursday May 11th, 2023. The fireside chat is scheduled to take place on Tuesday, May 9, 2023, at 3:00 PM PT.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received approval from the U.S. FDA for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.

CONTACT:

Investor Relations Email: ir@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 4

Media Relations: Email: media@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 6